Abstract 3847: Inhibition of GCN2 sensitizes ASNS-downregulated cancer cells to asparaginase by disrupting amino acid response
Akito Nakamura, Takahito Hara(Takeda (Japan)), Osamu Kurasawa(Takeda (Japan)), Ryuichi Nishigaki(Takeda (Japan)), Chisato Takahara(Takeda (Japan)), Yasuko Tsuchiya(Takeda (Japan)), Daisuke Tomita(Takeda (Japan)), Ayumi Kawamura(Takeda (Japan)), Tadahiro Nambu(Takeda (Japan)), Yuka Hasegawa(Kyoto Prefectural University of Medicine), Akito Hata(Takeda (United States)), Jun Fujimoto(Takeda (Japan)), Yoshinori Satomi(Takeda (Japan)), Kosei Toyoshima(Takeda (Japan)), Shunsuke Ebara(Takeda (Japan))
Cited by 0
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116
Androgen Receptor and Invasion in Prostate Cancer
|Cancer Research|2008|115